Adopted by the board of directors on 17 July 2014, and amended by the board of directors on 11 December 2020.
This Policy aims to set out the approach to achieving diversity for the board of directors (the “Board”) of Hutchison China MediTech Limited (the “Company”).
The Company recognises the benefits of a Board that possesses a balance of skills, experience, expertise, independence and knowledge and diversity of perspectives appropriate to the requirements of the businesses of the Company.
The Company maintains that Board appointment should be based on merit that complements and expands the skills, experience, expertise, independence and knowledge of the Board as a whole, taking into account gender, age, professional experience and qualifications, cultural and educational background, and any other factors that the Board might consider relevant and applicable from time to time towards achieving a diverse Board.
The nomination committee of the Company (the “Nomination Committee”) is responsible for reviewing the structure, size and composition of the Board, selecting the individuals to be nominated as Directors, reviewing succession plan of Directors and making recommendation on these matters to the Board for approval to ensure that it has a balanced composition of skills, experience, expertise, independence and knowledge appropriate to the requirements of the businesses of the Company, with due regard to the benefits of diversity on the Board.
The Nomination Committee reviews and monitors from time to time the implementation of this Policy to ensure its effectiveness, makes recommendation on any revisions as may be required to the Board for approval at an appropriate time set measurable objectives for achieving Board diversity.
A summary of this Policy and any measurable objectives which the Company has set for implementing this Policy, and progress on achieving those objectives, will be disclosed in the Corporate Governance Report of the Annual Report of the Company.